New Stock News | British biopharmaceutical company Allergy Therapeutics considers listing in Hong Kong.

According to the Zhixun Financial APP, Allergy Therapeutics, a biopharmaceutical company listed on the AIM market in the UK, announced on November 6 that it is currently evaluating the possibility of a dual listing on the main board of the Hong Kong Stock Exchange. If the decision is made to proceed, the company plans to complete the listing in the first half of 2026. The company emphasized that the listing application on the Hong Kong Stock Exchange requires approval from both the Hong Kong Stock Exchange and the Hong Kong Securities and Futures Commission.